Key Insights

Highlights

Treatment Research

3 treatments under study, led by Doxorubicin

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03111069Phase 1Withdrawn

Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children

Showing all 1 trials

Research Network

Common Treatments

  • Doxorubicin1
  • Intraoperative Radiation1
  • Abdominal Surgery1

Active Sponsors

  • M.D. Anderson Cancer Center1

Top Investigators

Related Conditions

  • Malignant Neoplasms Of Mesothelial And Soft Tissue1
  • Rhabdomyosarcoma Pelvic1

Activity Timeline